Brilinta approved in the US to reduce the risk of a first heart attack or stroke in high-risk patients with coronary artery disease
1 June 2020 07:00 BST Brilinta approved in the US to reduce the risk of a first heartattack or stroke in high-risk patients with coronary artery disease New Brilinta indication expands treatment to high-riskcoronary patients without a history of stroke or heart attack AstraZeneca's Brilinta (ticagrelor) has been approved in the US to reduce the risk of a first heart attack or stroke in high-risk patients with coronary artery disease (CAD), the most common type of heart disease. The approval by the US Food and Drug Administration (FDA) was based on positive results from the